How medtech can finally win on supply chain efficiency

Medtech lags behind in supply chain efficiency and margin performance

Medtech should be leading in operational excellence. Compared to industries like technology and aerospace, where companies such as Apple, TransDigm Group, Howmet Aerospace, and Eli Lilly consistently expand margins while cutting inventory, medtech is underperforming. Instead of boosting efficiency, it’s seeing both lower gross margins and higher inventory levels. This combination points to a deeper structural issue: the industry’s supply chains are not designed for speed or adaptability.

The operational health of a company isn’t measured by growth alone; it’s measured by how well capital is used to support that growth. Medtech firms face a widening gap between cost efficiency, how much value is extracted from every dollar, and capital efficiency, how well assets are optimized. From 2019 to 2025, the largest pure-play medtech companies saw gross margins fall by 149 basis points and days inventory outstanding (DIO) rise by 21 days. These results suggest that the sector, despite its innovation in product design, has not matched that same innovation in its operations.

C-suite leaders should look beyond temporary fluctuations and evaluate systemic misalignment. The problem isn’t lack of effort, it’s direction. While other industries have achieved the balance between growth and efficiency through better digital integration and supply alignment, medtech remains constrained by legacy systems and regulatory caution. The path forward isn’t incremental improvement but rethinking what operational excellence should mean in a post-pandemic, AI-driven economy. The companies that move first will redefine industry standards and raise investor confidence simultaneously.

Pandemic aftereffects and structural constraints

The pandemic didn’t just disrupt medtech supply chains, it exposed their fragility. Before 2020, the system was already under strain from complexity, slow decision cycles, and fragmented supplier relationships. When COVID-19 halted elective surgeries, supply levels spiked. Once demand returned, it outpaced production capabilities. Companies responded by flooding their networks with buffer stock, prioritizing supply continuity over efficiency.

Now, years later, those choices remain part of the system’s DNA. Even as production and demand normalize, DIO remains 17% above 2019 levels. That means companies are still holding significantly more inventory than before. While resilience was essential during the crisis, maintaining these elevated inventory levels is now a drag on capital efficiency. The challenge is to pivot from reactive strategies to intentional, data-driven supply chain optimization.

Executives should realize that resilience and efficiency are not opposing goals, they’re sequential ones. First, achieve stability; then, refine it. Pandemic-era workflows must now evolve into leaner, technology-enabled systems that balance readiness with capital discipline. The risk of standing still is clear: continued margin erosion and lower market valuation.

Growth-driven valuations now demand operational reinvention

For years, medtech companies have relied on growth to sustain valuations. That model is no longer reliable. Investors are pushing for proof of efficiency, not just expansion. Growth without supporting operational strength has become a liability. Margins are slipping, cost structures are rigid, and volatility across supply chains is eroding confidence. The industry must now demonstrate that it can grow smarter, balancing innovation with efficiency at every stage of its operations.

The opportunity is significant. Closing the performance gap between current medtech operations and those of the top-performing industries could unlock more enterprise value than many mergers and acquisitions typically deliver, without integration risks or complexity. Efficiency is fast becoming a central factor in shareholder value, with investors recognizing that sustainable value creation now depends on both capital discipline and cost performance.

Executives must act with clarity and intent. Growth is still essential, but it has to be underpinned by operational systems that can scale predictably and profitably. Market volatility and pricing pressure make it clear that efficiency is no longer optional, it is strategic. The first companies to demonstrate consistent margin expansion alongside inventory efficiency will not just improve their balance sheets; they will redefine investor expectations for the entire sector. Medtech leaders need to view operational reinvention not as maintenance but as competitive positioning.

Systemic barriers inhibit medtech’s operational transformation

Medtech’s supply chain challenges are not isolated, they are built into its structure. Strict quality management systems (QMS), lengthy regulatory approval processes, and fragmented supply bases have created operational inertia. Each constraint feeds the next. Change control procedures slow execution; supplier fragmentation adds cost and complexity; and an overabundance of SKUs increases forecasting errors and stock requirements. As a result, medtech operations run with higher friction and less flexibility than those in comparable industries.

High gross margins across the sector, often exceeding 60%, have dulled the sense of urgency for transformation. Traditional attempts at efficiency, lean programs, working capital task forces, and cost-reduction campaigns, succeed only temporarily because they target symptoms, not foundations. True improvement requires redesigning how operational decisions are made and how systems interact across regulatory, supply, and commercial domains.

C-suite leaders must see that medtech’s barriers are deep-rooted but solvable. Structural change means questioning long-standing operational assumptions, from supplier strategies to inventory philosophies. It also means shifting from isolated initiatives to holistic redesign. The challenge is not simply technical, it is cultural. Leadership alignment across functions and a willingness to challenge entrenched processes will be the dividing line between those who adapt and those who continue to erode margins. The goal should be operational architectures that are not constrained by habit but driven by purpose.

Historical “Right” decisions now compound medtech’s inefficiencies

Much of medtech’s operational complexity is the outcome of decisions that once made perfect sense. Expanding product portfolios to satisfy surgeon preferences, building safety stock to manage compliance risks, and maintaining long supplier qualification processes were all rational, risk-averse choices. These actions prioritized patient safety and reliability, core values that define the industry. But when repeated over decades and across acquisitions, these same decisions accumulated into structural inefficiencies that now limit speed, scalability, and cost control.

Today, the result is a network of overlapping product lines, too many SKUs, and slower production cycles than the industry can afford. These are not failures in leadership, they are artifacts of a safety-first culture. However, with rising investor expectations and margin pressures, what was once considered prudent has become a constraint. The companies that succeed next will be those willing to challenge the sum of these legacy practices, identifying which traditions still serve the business and which now block progress.

Executives should approach this re-evaluation process with balance. The goal is not to discard the industry’s cautious DNA but to evolve it. Leadership teams must separate operational processes that protect patients from those maintained out of habit. Rationalizing product complexity, supplier networks, and production flows can be done without undermining quality or compliance. The opportunity lies in converting historically rigid systems into adaptive frameworks that meet modern performance demands. This is a strategic reset, not a cleanup effort, it’s what will distinguish future high performers.

Six strategic steps to achieve cost and capital efficiency in medtech

Becoming a cost and capital high performer in medtech requires more than marginal cost reduction; it demands structural change. Six deliberate moves define the path forward. First, align operations with commercial strategy. High-growth segments need speed and scalability; mature product lines require cost control. One operating model cannot serve all categories. Second, take an unconstrained view of the future supply chain. Redefine it from the ground up to identify which assumptions are fixed by regulation and which exist only because they have never been questioned.

Third, combine radical simplification with zero-based redesign. This means cutting unnecessary SKUs, focusing footprint investments where they matter most, and rebuilding workflows for efficiency rather than compliance comfort. Fourth, optimize end-to-end coordination across functions. Many inefficiencies exist at the intersections between planning, manufacturing, and quality. Shared metrics and clear accountability can remove those gaps. Fifth, apply risk-based quality management. Not every change carries equal risk; distinguishing between high- and low-risk processes accelerates decisions without compromising safety. Finally, modernize through AI and Industry 4.0 tools such as predictive analytics, smart factories, and connected systems. These technologies are now fast to deploy and yield measurable results when built on a simplified foundation.

For C-suite leaders, this is not a technical checklist but an operational philosophy. The effectiveness of these six moves depends on leadership alignment, cultural openness to simplification, and readiness to invest in foundational change before digital transformation. Many organizations attempt to digitize complexity rather than eliminate it, slowing results. Executives who first simplify and standardize, and then automate, will see compounding benefits in cost savings, capital efficiency, and speed to market. The timing is urgent; the race toward operational reinvention is already underway.

A limited window of opportunity to gain lasting competitive advantage

The current moment presents a narrow but powerful opportunity for medtech companies. After years of volatility, service levels have stabilized and operational visibility has improved. This is the time to move from recovery to reinvention. Companies that redesign their supply chains now, streamlining complexity, reducing waste, and integrating smarter digital systems, will unlock a lasting advantage. Those that delay will face higher costs, slower recovery cycles, and diminishing investor confidence as competitors move ahead.

Operational efficiency and margin expansion can no longer be postponed. The industry stands at a pivot point where performance leadership will emerge from those willing to challenge long-entrenched processes. The ability to increase margins while reducing inventory, something yet to be achieved across much of medtech, is the clearest indicator of a well-optimized supply chain. Achieving this dual success requires commitment to structural change, not short-term adjustments.

C-suite executives must recognize the urgency of timing. Every sector experiences windows of disruption that reset competitive standards, and medtech is now at that threshold. The companies that act decisively and invest in structural transformation will define the next phase of operational leadership. Executives should orchestrate change rapidly but deliberately, aligning commercial, manufacturing, and regulatory teams to execute on efficiency goals. Once competitors adapt, the differentiation gap narrows, making early action the most valuable strategic move available today.

Concluding thoughts

Medtech is standing at a defining point. The last few years have proven that growth alone can no longer sustain value. Efficiency, resilience, and adaptability are now the real measures of performance. The companies that accept this shift, and act on it, will lead the next phase of industry transformation.

This isn’t about trimming costs or running leaner supply chains. It’s about designing smarter systems that align strategy, operations, and technology in a unified direction. Leaders who simplify before they automate, who challenge legacy assumptions, and who make cross-functional accountability non‑negotiable will outperform the market.

The opportunity window is open, but not for long. Those who move now, rebuilding their operational backbone with clarity and courage, will set the new benchmark for what operational excellence in medtech truly means.